I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Canada

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Neuroscience AMCP 2025
Roche and Genentech at

AMCP 2025

March 31 - April 03
TX, USA
amcp.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Personalised Healthcare
Apr 7 / Roche and Genentech
IMPACT OF SELF-FUNDED VERSUS FULLY INSURED COMMERCIAL HEALTH PLANS ON DRUG PATIENT LIABILITY
Several states are considering policies to address concerns about patient affordability of drugs, including examining the impact of health plan benefit design on patient financial liability. ● Commercial health plans fall typically into one of two categories: fully insured (FI) plans (state-regulated) and self-funded (SF) plans (federally regulated). ● Employers who choose to self-fund have more control over their benefits; however, little is known about how benefit designs and patient cost sharing differ between SF and FI health plans.
HealthTech Real World Data - Real World Evidence AMCP-2025

Sign up or login to unlock the full suite of MEDICALLY features
Personalised Healthcare
Apr 7 / Roche and Genentech
IS UTILIZATION OF COPAY ASSISTANCE CORRELATED WITH LIST AND NET PRICES OF MEDICINES?
Copay assistance programs reduce patients’ out-of-pocket costs for medications, which can lead to improved clinical and more equitable outcomes.1,2 – However, it is believed that these programs may lead to higher medication prices.3 – Despite this belief, there is limited real-world evidence of the association between copay assistance utilization and medication prices.
HealthTech Real World Data - Real World Evidence AMCP-2025

Sign up or login to unlock the full suite of MEDICALLY features
Apr 3 / Roche and Genentech
Treatment Patterns Among Medicare Advantage Plan Beneficiaries Diagnosed with Neovascular Age-Related Macular Degeneration Who Initiated Faricimab▼ Treatment
This presentation reports the real-world baseline characteristics, treatment patterns, and HCRU in patients initiating faricimab▼ for neovascular age-related macular degeneration (2022–2023). Treatment patterns and HCRU were evaluated for the 12 months before and after faricimab▼ initiation using claims analysis; results were stratified according to history of prior anti-VEGF therapy (VEGF-experienced vs VEGF-naive).
Ophthalmology Neovascular Age Related Macular Degeneration AMCP-2025
04:30 PM
Duration 180mins TX, USA
IS UTILIZATION OF COPAY ASSISTANCE CORRELATED WITH LIST AND NET PRICES OF MEDICINES?
Thomas Majda, Danny Sheinson, Rongrong Wang, Anna Hung, William B. Wong
HealthTech

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 180mins TX, USA
IMPACT OF SELF-FUNDED VERSUS FULLY INSURED COMMERCIAL HEALTH PLANS ON DRUG PATIENT LIABILITY
Danny Sheinson, Zhiyu Xia, Stacey Kowal, William B. Wong
HealthTech

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 90mins TX, USA
Muscle MRI outcomes in patients with Duchenne Muscular Dystrophy treated with delandistrogene moxeparvovec: Findings from EMBARK Part 1
Krista Vandenborne, Glenn Walter, Volker Straub, Rebecca Willcocks, Sean Forbes, Sravya Ennamuri, Kai Ding, Carol Reid, Alexander P. Murphy, Marianna Manfrini, Jacob S. Elkins, Louise R. Rodino-Klapac
Neuroscience | Duchenne Muscular Dystrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 90mins TX, USA
Cardiac MRI Outcomes in Patients with Duchenne Muscular Dystrophy Treated with Delandistrogene Moxeparvovec: Findings from EMBARK Part 1
Glenn Walter, Krista Vandenborne, John Bourke, Jonathan Soslow, Stefanie Mason, Emanuel Palatinsky, Christoph Wandel, Kai Ding, Carol Reid, Alexander P. Murphy, Marianna Manfrini, James Richardson, Jacob S. Elkins
Neuroscience | Duchenne Muscular Dystrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:00 PM
Duration 180mins TX, USA
Treatment Patterns Among Medicare Advantage Plan Beneficiaries Diagnosed with Neovascular Age-Related Macular Degeneration Who Initiated Faricimab▼ Treatment
Ko S, Tabano D, Saundankar V, Sheer R, Suehs B, Bonine N
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 180mins TX, USA
Treatment Patterns Among Medicare Advantage Plan Beneficiaries Diagnosed with Diabetic Macular Edema Who Initiated Faricimab▼ Treatment
Ko S, Tabano D, Saundankar V, Sheer R, Suehs B, Bonine N
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.